Recombinant DNA Advisory Committee - 7/31/90 
under "Other Business" to the beginning of paragraph four. The 
first sentence of the first paragraph should introduce the topic 
of the public hearings and make it clear that the first three 
paragraphs have to do with the public meetings, with the 
following text pertaining to human gene therapy. 
Dr. Riley moved adoption of the minutes with this correction. 
Mr. Mannix said he also had read the minutes and agreed with Dr. 
Riley's suggestion for a change in wording, and he seconded the 
motion. 
Dr. McGarrity offered a friendly amendment in the form of a 
request to have ORDA staff research the vote on a motion found on 
page 14 of the minutes. Currently the minutes reflect that the 
vote was "passed by majority vote." He asked that the actual 
tally of votes be inserted at this point. Dr. Riley accepted 
this as a friendly amendment. 
There being no further discussion on the motion. Dr. McGarrity 
called for a vote on the motion. The motion passed by a vote of 
15 in favor, none opposed, and 2 abstentions. 
Dr. McGarrity said, before getting into the discussion of the 
SCID-adenosine deaminase (ADA) deficiency protocol, that he felt 
it was important for members of the RAC who did not attend the 
meeting of the HGTS to get a flavor of what had been presented 
and discussed. He expressed a desire that ORDA include the 
appropriate portion of the minutes of the HGTS meetings of June 1 
(Attachment B) and July 30, 1990, into the minutes of this 
meeting (See Attachment B & C) . Furthermore, he said the same 
should be done with discussions of the proposal for human gene 
therapy involving the proposed use of tumor necrosis factor 
(TNF) . He then called upon Dr. Gellert to discuss the SCID-ADA 
protocol. 
III. PRESENTATION AND DISCUSSION OF PROPOSED ADDITION TO APPENDIX D 
OF THE ”NIH GUIDELINES” REGARDING HUMAN GENE THERAPY PROTOCOL 
ENTITLED *»TREATMENT OF SEVERE COMBINED IMMUNE DEFICIENCY (SCID) 
DUE TO ADENOSINE DEAMINASE (ADA) DEFICIENCY WITH AUTOLOGOUS 
LYMPHOCYTES TRANSDUCED WITH A HUMAN ADA GENE." 
Dr. Gellert noted that the HGTS had discussed this protocol at 
both the June 1, 1990, and July 30, 1990, meetings. At the June 
1, 1990, meeting, the protocol had been tentatively approved 
subject to the following provisos: 
1. That the consent form be revised, reviewed, and 
accepted by the RAC at its next meeting; 
[116] 
Recombinant DNA Research, Volume 14 
